سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Tsai, Sheng-Ta, Wei, Tzu-Hsuan, Yang, Yu-Wan, Lu, Ming-Kuei, San, Shao, Tsai, Chon-Haw, Lin, Yi-Wen. (1400). Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine. , 24(10), 1336-1345. doi: 10.22038/ijbms.2021.56156.12531
Sheng-Ta Tsai; Tzu-Hsuan Wei; Yu-Wan Yang; Ming-Kuei Lu; Shao San; Chon-Haw Tsai; Yi-Wen Lin. "Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine". , 24, 10, 1400, 1336-1345. doi: 10.22038/ijbms.2021.56156.12531
Tsai, Sheng-Ta, Wei, Tzu-Hsuan, Yang, Yu-Wan, Lu, Ming-Kuei, San, Shao, Tsai, Chon-Haw, Lin, Yi-Wen. (1400). 'Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine', , 24(10), pp. 1336-1345. doi: 10.22038/ijbms.2021.56156.12531
Tsai, Sheng-Ta, Wei, Tzu-Hsuan, Yang, Yu-Wan, Lu, Ming-Kuei, San, Shao, Tsai, Chon-Haw, Lin, Yi-Wen. Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine. , 1400; 24(10): 1336-1345. doi: 10.22038/ijbms.2021.56156.12531

Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine

Iranian Journal of Basic Medical Sciences
دوره 24، شماره 10، دی 2021، صفحه 1336-1345    اصل مقاله (1.22 M)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2021.56156.12531
نویسندگان
Sheng-Ta Tsai1، 2، 3؛ Tzu-Hsuan Wei4؛ Yu-Wan Yang1، 5؛ Ming-Kuei Lu1، 3، 5؛ Shao San6؛ Chon-Haw Tsai1، 3، 5؛ Yi-Wen Lin* 2، 7
1Department of Neurology, China Medical University Hospital, Taichung, Taiwan
2Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan
3Everflourish Neuroscience and Brain Disease Center, China Medical University Hospital, Taichung, Taiwan
4Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan
5College of Medicine, China Medical University, Taichung, Taiwan
6Department of Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan, Taiwan
7Chinese Medicine Research Center, China Medical University, Taichung, Taiwan
چکیده
Objective(s): Parkinson’s disease (PD) is a common progressive neurodegeneration disease. Its incidence increases with age and affects about 1% of people over 60. Incidentally, transient receptor potential V1 (TRPV1) and its relation with neuroinflammation in mouse brain has been widely reported.
Materials and Methods: We used 6-hydroxydopamine (6-OHDA) to induce PDD in mice. We then used the Morris water maze and Bio-Plex to test learning and inflammatory mediators in mouse plasma. Western blotting and immunostaining were used to examine TRPV1 pathway in the hippocampus and medial prefrontal cortex (mPFC).
Results: On acquisition days 3 (Control = 4.40 ± 0.8 sec, PDD = 9.82 ± 1.52 sec, EA = 5.04 ± 0.58 sec, Riva = 4.75 ± 0.87 sec; P=0.001) and 4, reversal learning days 1, 2, 3 (Control = 2.86 ± 0.46 sec, PDD = 9.80 ± 1.83 sec, EA = 4.6 ± 0.82 sec, Riva = 4.6 ± 1.03 sec; P=0.001) and 4, PDD mice showed significantly longer escape latency than the other three groups. Results showed that several cytokines were up-regulated in PDD mice and reversed by EA and rivastigmine. TRPV1 and downstream molecules were up-regulated in PDD mice and further reversed by EA and rivastigmine. Interestingly, α7 nicotinic receptors and parvalbumin levels in both the hippocampus and prefrontal cortex increased in EA-treated mice, but not in rivastigmine-treated mice.
Conclusion: Our results showed that TRPV1 played a role in the modulation of neuroinflammation of PDD, and could potentially be a new target for treatment.
کلیدواژه‌ها
Electroacupuncture؛ Hippocampus؛ Neuroinflammation؛ Parkinson’s disease dementia؛ Rivastigmine؛ Transient receptor potential V1
مراجع
1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844.
2. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 2011; 26:1814-1824.
3. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 2010; 9:1200-1213.
4. Diaz NL, Waters CH. Current strategies in the treatment of Parkinson’s disease and a personalized approach to management. Expert Rev Neurother 2009; 9:1781-1789.
5. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol 2017; 13:217-231.
6. Zinger A, Barcia C, Herrero MT, Guillemin GJ. The involvement of neuroinflammation and kynurenine pathway in Parkinson’s disease. Parkinsons Dis 2011; 1-11.
7. Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol 2020; 16:303-318.
8. Kong WL, Peng YY, Peng BW. Modulation of neuroinflammation: role and therapeutic potential of TRPV1 in the neuro-immune axis. Brain Behav Immun 2017; 64:354-366.
9. Luo L, Wang Y, Li B, Xu L, Kamau PM, Zheng J, et al. Molecular basis for heat desensitization of TRPV1 ion channels. Nat Commun 2019; 10:2134-2146.
10. Li M, Zhu M, Xu Q, Ding F, Tian Y, Zhang M. Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson’s disease. Biochem Biophys Res Commun 2020; 521:868-873.
11. Marrone MC, Morabito A, Giustizieri M, Chiurchiù V, Leuti A, Mattioli M, et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun 2017; 8:15292-15310.
12. Thacker EL, O’Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007; 68:764-768.
13. Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, et al. Tobacco smoking and the risk of Parkinson disease: a 65-year follow-up of 30,000 male British doctors. Neurology 2020; 94:1-7.
14. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002; 53:590-605.
15. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA, et al. Pathology associated with sporadic Parkinson’s disease--where does it end? J Neural Transm Suppl 2006:89-97.
16. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004; 29:108-116.
17. Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 1984; 15:415-418.
18. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351:2509-2518.
19. Oh YS, Kim JS, Lee PH. Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson’s disease dementia. J Mov Disord 2015; 8:98-102.
20. Liu Y, Zeng X, Hui Y, Zhu C, Wu J, Taylor DH, et al. Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson’s disease. Neuropharmacology 2015; 91:87-96.
21. Foucault-Fruchard L, Antier D. Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases. Neural Regen Res 2017; 12:1418-1421.
22. Liao H-Y, Lin Y-W. Electroacupuncture reduces cold stress-induced pain through microglial inactivation and transient receptor potential V1 in mice. Chin Med 2021; 16:43-58.
23. Lee SH, Lim S. Clinical effectiveness of acupuncture on Parkinson disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2017; 96:1-9.
24. Kim SR, Lee TY, Kim MS, Lee MC, Chung SJ. Use of complementary and alternative medicine by Korean patients with Parkinson’s disease. Clin Neurol Neurosurg 2009; 111:156-160.
25. Pecci C, Rivas MJ, Moretti CM, Raina G, Ramirez CZ, Díaz S, et al. Use of complementary and alternative therapies in outpatients with Parkinson’s disease in Argentina. Mov Disord 2010; 25:2094-2098.
26. Lökk J, Nilsson M. Frequency, type and factors associated with the use of complementary and alternative medicine in patients with Parkinson’s disease at a neurological outpatient clinic. Parkinsonism Relat Disord 2010; 16:540-544.
27. Tan LC, Lau PN, Jamora RD, Chan ES. Use of complementary therapies in patients with Parkinson’s disease in Singapore. Mov Disord 2006; 21:86-89.
28. Wei TH, Hsieh CL. Effect of acupuncture on the p38 Signaling pathway in several nervous system diseases: a systematic review. Int J Mol Sci 2020; 21:1-39.
29. Jang J-H, Yeom M-J, Ahn S, Oh J-Y, Ji S, Kim T-H, et al. Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson’s disease. Brain Behav Immun 2020; 89:641-655.
30. Lu KW, Yang J, Hsieh CL, Hsu YC, Lin YW. Electroacupuncture restores spatial learning and downregulates phosphorylated N-methyl-D-aspartate receptors in a mouse model of Parkinson’s disease. Acupunct Med 2017; 35:133-141.
31. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1:848-858.
32. Lee Y, Lee S, Chang S-C, Lee J. Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention. Arch Pharm Res 2019; 42:416-425.
33. Ding SS, Hong SH, Wang C, Guo Y, Wang ZK, Xu Y. Acupuncture modulates the neuro–endocrine–immune network. QJM Int J Med 2013; 107:341-345.
34. Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain 2001; 124:2503-2512.
35. Murray AJ, Woloszynowska-Fraser MU, Ansel-Bollepalli L, Cole KLH, Foggetti A, Crouch B, et al. Parvalbumin-positive interneurons of the prefrontal cortex support working memory and cognitive flexibility. Sci Rep 2015; 5:16778-16792.
36. Caillard O, Moreno H, Schwaller B, Llano I, Celio MR, Marty A. Role of the calcium-binding protein parvalbumin in short-term synaptic plasticity. Proc Nati Acad Sci 2000; 97:13372-13377.
37. Nie J, Wei X, Xu X, Li N, Li Y, Zhao Y, et al. Electro-acupuncture alleviates adolescent cocaine exposure-enhanced anxiety-like behaviors in adult mice by attenuating the activities of PV interneurons in PrL. Faseb j 2020; 34:11913-11924.
38. Chao D, Shen X, Xia Y. From acupuncture to interaction between δ-opioid receptors and Na (+) channels: a potential pathway to inhibit epileptic hyperexcitability. Evid Based Complement Alternat Med 2013; 216016-216033.
39. Hurtado-Zavala JI, Ramachandran B, Ahmed S, Halder R, Bolleyer C, Awasthi A, et al. TRPV1 regulates excitatory innervation of OLM neurons in the hippocampus. Nat Commun 2017; 8:15878-15898.
40. Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT, et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:249-258.
41. Rochester L, Hetherington V, Jones D, Nieuwboer A, Willems AM, Kwakkel G, et al. Attending to the task: interference effects of functional tasks on walking in Parkinson’s disease and the roles of cognition, depression, fatigue, and balance. Arch Phys Med Rehabil 2004; 85:1578-1585.
42. Reingold JL, Morgan JC, Sethi KD. Rivastigmine for the treatment of dementia associated with Parkinson’s disease. Neuropsychiatr Dis Treat 2007; 3:775-783.
43. Chen S, Bai L, Xu M, Wang F, Yin L, Peng X, et al. Multivariate granger causality analysis of acupuncture effects in mild cognitive impairment patients: an fMRI study. Evid Based Complement Alternat Med 2013; 127271-127283.
44. Abraham TS, Chen ML, Ma SX. TRPV1 expression in acupuncture points: response to electroacupuncture stimulation. J Chem Neuroanat 2011; 41:129-136.
45. Chen HC, Chen MY, Hsieh CL, Wu SY, Hsu HC, Lin YW. TRPV1 is a responding channel for acupuncture manipulation in mice peripheral and central nerve system. Cell Physiol Biochem 2018; 49:1813-1824.
46. Choowanthanapakorn M, Lu K-W, Yang J, Hsieh C-L, Lin Y-W. Targeting TRPV1 for body weight control using TRPV1−/− mice and electroacupuncture. Sci Rep 2015; 5:17366-17375.
47. Lin Y-W, Chou AIW, Su H, Su K-P. Transient receptor potential V1 (TRPV1) modulates the therapeutic effects for comorbidity of pain and depression: the common molecular implication for electroacupuncture and omega-3 polyunsaturated fatty acids. Brain Behav Immun 2020; 89:604-614.
48. Wu SY, Chen WH, Hsieh CL, Lin YW. Abundant expression and functional participation of TRPV1 at zusanli acupoint (ST36) in mice: mechanosensitive TRPV1 as an “acupuncture-responding channel”. BMC Complement Altern Med 2014; 14:96-111.
49. Lin J-G, Hsieh C-L, Lin Y-W. Analgesic effect of electroacupuncture in a mouse fibromyalgia model: Roles of TRPV1, TRPV4, and pERK. PLoS One 2015; 10:1-16.
50. Yen CM, Hsieh CL, Lin YW. Electroacupuncture reduces chronic fibromyalgia pain through attenuation of transient receptor potential vanilloid 1 signaling pathway in mouse brains. Iran J Basic Med Sci 2020; 23:894-900.
51. Chen W-H, Tzen JTC, Hsieh CL, Chen YH, Lin T-J, Chen S-Y, et al. Attenuation of TRPV1 and TRPV4 expression and function in mouse inflammatory pain models using electroacupuncture. Evid Based Complement Alternat Med 2012; 1-12.
52. Lu K-W, Hsu C-K, Hsieh C-L, Yang J, Lin Y-W. Probing the effects and mechanisms of electroacupuncture at ipsilateral or contralateral ST36–ST37 acupoints on CFA-induced inflammatory pain. Sci Rep 2016; 6:22123-22134.
53. Yang J, Hsieh C-L, Lin Y-W. Role of transient receptor potential vanilloid 1 in electroacupuncture analgesia on chronic inflammatory pain in mice. BioMed Res Int 2017; 1-8.
54. Liao H-Y, Hsieh C-L, Huang C-P, Lin Y-W. Electroacupuncture attenuates CFA-induced inflammatory pain by suppressing Nav1.8 through S100B, TRPV1, opioid, and adenosine pathways in mice. Sci Rep 2017; 7:42531-42544.
55. Yen CM, Wu TC, Hsieh CL, Huang YW, Lin YW. Distal electroacupuncture at the LI4 acupoint reduces CFA-induced inflammatory pain via the brain TRPV1 signaling pathway. Int J Mol Sci 2019; 20:1-13.
56. Hsu HC, Hsieh CL, Lee KT, Lin YW. Electroacupuncture reduces fibromyalgia pain by downregulating the TRPV1-pERK signalling pathway in the mouse brain. Acupunct Med 2020; 38:101-108.
57. Inprasit C, Lin YW. TRPV1 responses in the cerebellum lobules V, VIa and VII using electroacupuncture treatment for inflammatory hyperalgesia in murine model. Int J Mol Sci 2020; 21:1-16.
58. Inprasit C, Lin Y-W, Huang C-P, Wu S-Y, Hsieh C-L. Targeting TRPV1 to relieve motion sickness symptoms in mice by electroacupuncture and gene deletion. Sci Rep 2018; 8:10365-10375.
59. Guo ZL, Fu LW, Su HF, Tjen ALSC, Longhurst JC. Role of TRPV1 in acupuncture modulation of reflex excitatory cardiovascular responses. Am J Physiol Regul Integr Comp Physiol 2018; 314:1-12.
60. Wang S-J, Yang H-Y, Xu G-S. Acupuncture alleviates colorectal hypersensitivity and correlates with the regulatory mechanism of TrpV1 and p-ERK. Evid Based Complement Alternat Med 2012; 483123-483133.

آمار
تعداد مشاهده مقاله: 988
تعداد دریافت فایل اصل مقاله: 653